← All stocks

PUMA BIOTECHNOLOGY, INC.

PBYI Scheduled selling only

CIK 0001401667 #3143 in the set updated 17 Sep 2026

Bought (1 mo)

$0.00

out of their own pocket, the only kind of buying there is

Sold (1 mo)

$612.49K

$45.50K on a plan · $566.99K straight out of an exercise

Sold at will

$0.00

0 of 2 sales

Net

−$612.49K

$0.00 against sales at will

By person

11 insiders · 2 transactions

71.1×

Alan H. Auerbach holds 71.1 times base salary in stock. $66.25M of shares against $931.33K in salary for 2025.

Salary from the company's own proxy. The shares are what Alan H. Auerbach last reported holding, valued at $9.12, the price Common Stock was last bought or sold at on the open market here, on 14 Sep 2026.

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

Cesano Alessandra

Director

—

$566.99K (1) scheduled

−$566.99K

56,700

0.1098%

$517.27K

+5.0%

WILSON TROY EDWARD

Director

—

$45.50K (1) scheduled

−$45.50K

55,300

0.1071%

$504.50K

+98.2%

AUERBACH ALAN H

President and CEO

—

7,261,671

14.07%

$66.25M

+2.8%

NOUGUES MAXIMO F

Chief Financial Officer

—

230,637

0.4468%

$2.10M

+41.9%

HUNT DOUGLAS M

See Remarks

—

196,841

0.3813%

$1.80M

+47.7%

Ludwig Jeffrey Jerome

Chief Commercial Officer

—

156,792

0.3037%

$1.43M

+32.4%

Stuglik Brian M

Director

—

113,858

0.2206%

$1.04M

+49.7%

Dorval Allison

Director

—

90,780

0.1759%

$828.19K

+51.3%

MILLER MICHAEL PATRICK

Director

—

81,000

0.1569%

$738.96K

+72.3%

MOYES JAY M

Director

—

58,322

0.1130%

$532.07K

+20.7%

Senderowicz Adrian

Director

—

27,000

0.0523%

$246.32K

0.0%

Individual transactions

Nothing of that kind in this period.

What was left out

Form 4 filings counted 2

Amendments (4/A) skipped 0

Filings about a different issuer 0

Unreadable filings 0

Joint filings 0

Sales on a Rule 10b5-1 plan 1

Sales straight out of an exercise 1

Sales at will 0

Transactions with no price 0

Shares from compensation/vesting 50,000

History held since 14 Oct 2016